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The human immunodeficiency virus (HIV) integrase (IN) must covalently join the viral cDNA into a host chromosome for productive
HIV infection. L-Chicoric acid (L-CA) enters cells poorly but is a potent inhibitor of IN in vitro. Using quantitative real-time polymerase
chain reaction (PCR), L-CA inhibits integration at concentrations from 500 nM to 10 AM but also inhibits entry at concentrations above 1 AM.
Using recombinant HIV IN, steady-state kinetic analyses with L-CA were consistent with a noncompetitive or irreversible mechanism of
inhibition. IN, in the presence or absence of L-CA, was successively washed. Inhibition of IN diminished, demonstrating that L-CA was
reversibly bound to the protein. These data demonstrate that L-CA is a noncompetitive but reversible inhibitor of IN in vitro and of HIV
integration in vivo. Thus, L-CA likely interacts with amino acids other than those which bind substrate.
D 2004 Elsevier Inc. All rights reserved.Keywords: Real-time polymerase chain reaction; Acquired immune deficiency syndrome; Experimental therapeutics; Biochemistry; Steady-state kinetic
analyses; ProvirusIntroduction
The human immunodeficiency virus (HIV) is the causa-
tive agent of the acquired immune deficiency syndrome
(AIDS). Currently, treatment of HIV infection includes
inhibitors targeted at two of the three viral enzymes: reverse
transcriptase (RT) and protease (PR). Treatment with com-
binations of RT and PR inhibitors has proven effective in
reducing the levels of circulating virus to below detectable
levels in many individuals (Autran et al., 1997; Collier et
al., 1996; Gulick et al., 1997). The use of three-drug
combinations delays the onset of HIV drug resistance0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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sity, Nacogdoches, TX 75961, USA.(Baldanti et al., 2000); nevertheless, resistance occurs
(Baldanti et al., 2000; Conway et al., 2001). Indeed, HIV
that is resistant to both RT and PR inhibitors has been
described (Condra et al., 1995; Gao et al., 1993; Gu et al.,
1992, 1994; Gulnik et al., 1995; Swanstrom, 1994; Tisdale
et al., 1995). Moreover, the transmission of multiple drug-
resistant HIV has been reported (Hecht et al., 1998; Young
et al., 1998) and new infections with drug-resistant HIV
approaches 25% (UK Collaborative Group, 2001; Wegner
et al., 2000). It has been suggested that infection with drug-
resistant HIV may compromise future therapies using more
medications (Albrecht et al., 2001), justifying development
of agents targeted at steps other than RT and PR (Montaner
and Mellors, 2001).
Integrase (IN), the third HIV enzyme, catalyzes the
integration of a DNA copy of the viral genome into the
host cellular chromosome. IN is absolutely required for
productive infection (LaFemina et al., 1992; Sakai et al.,
1993; Stevenson et al., 1990; Wiskerchen and Muesing,
R.A. Reinke et al. / Virology 326 (2004) 203–2192041995) and therefore, inhibition of IN can directly affect the
viral life cycle (Hazuda et al., 2000; King et al., 1999;
Robinson et al., 1996a, 1996b and reviewed in Pommier
and Neamati, 1999; Robinson, 1998a). IN catalyzes the
insertion of the viral genome into a host cell’s chromosome
via a two-step mechanism. IN first catalyzes the removal of
two nucleotides from the 3V end of the viral long terminal
repeats (LTR), exposing a highly conserved CpA dinucle-
otide and a free 3V-hydroxyl group (Brown et al., 1989;
Fujiwara and Mizuuchi, 1988; Roth et al., 1990). The
exposed hydroxyl can then participate in a nucleophilic
attack on the target DNA, resulting in an integration
intermediate consisting of a covalent linkage between the
viral 3V end and the target DNA (Brown et al., 1989;
Fujiwara and Mizuuchi, 1988), thus generating a two
nucleotide overhang on the viral 5V end and an unpaired
gap in the target DNA. This intermediate is likely repaired
by host cellular DNA repair machinery (Bushman and
Craigie, 1991; Daniel et al., 1999; Miller et al., 1995),
resulting in a fully integrated provirus flanked by direct
repeats.
The two reactions catalyzed by IN in vivo, 3V-end
processing and strand transfer, can be studied in vitro using
recombinant purified IN and short oligonucleotide sub-
strates that resemble the viral LTRs (Bushman and Craigie,
1991; Chow, 1997; Chow and Brown, 1994; Sherman and
Fyfe, 1990; Sherman et al., 1992; Vincent et al., 1993). IN
can catalyze a third reaction, termed disintegration, which
resembles the reversal of integration. A DNA oligonucleo-
tide resembling a partially integrated DNA intermediate can
be resolved into two distinct entities (Chow, 1997; Chow
et al., 1992). Although the disintegration reaction has only
been described in vitro, it offers some distinct advantages
over the 3V-end processing and strand transfer reactions; in
particular, disintegration requires only the catalytic core
region of IN for catalysis, whereas the 3V-end processing
and strand transfer reactions require the full-length protein
(Chow et al., 1992; Robinson et al., 1996a). Disintegration
using the dumbbell substrate is also less likely to complicate
steady-state kinetic analyses, as only a single substrate and a
single product exist.
There has been substantial interest in developing inhi-
bitors of integration for use in HIV-infected individuals
(reviewed in Pommier and Neamati, 1999; Robinson,
1998a). Development of selective inhibitors of HIV inte-
gration that are nontoxic to cells has proven problematic. A
G octet oligonucleotide, AR177, was the first inhibitor to be
developed and tested in patients (Abrams et al., 1996;
Ojwang et al., 1994, 1995). Several classes of small mole-
cules that inhibit HIV replication, at least in part through
inhibition of IN, have been described previously (Hazuda
et al., 2000; King et al., 1999; Lin et al., 1999; Robinson et
al., 1996a, 1996b). L-Chicoric acid (L-CA), a dicaffeoyltar-
taric acid (DCTA), is one of the most potent and thoroughly
studied of these inhibitors (Beale and Robinson, 2000; King
and Robinson, 1998; McDougall et al., 1998; Robinson,1998a, 1998b; Robinson et al., 1996a, 1996b; Zhu et al.,
1999).
The dicaffeoylquinic acids (DCQAs) and dicaffeoyltarta-
ric acids (DCTAs) are natural product, sub-micromolar
inhibitors of HIV IN in biochemical assays, have favorable
therapeutic indices (TI) in tissue culture, and anti-HIV
activities in the range of 1–10 AM (Robinson et al.,
1996a, 1996b). The anti-IN properties of the DCTAs and
DCQAs were identified in a blinded fashion (Robinson et
al., 1996a, 1996b). In biochemical assays, the DCTAs and
the DCQAs do not inhibit gp120 binding to CD4 (McDou-
gall et al., 1998) or cell fusion (McDougall et al., 1998), and
they inhibit neither HIV RNase H (McDougall et al., 1998)
nor HIV RT when either poly rA-oligo dT or poly rC-oligo
dG template is used in ex vivo assays of RT activity
(McDougall et al., 1998). All of the above are true at
concentrations fully 100-fold higher than concentrations
necessary to inhibit HIV IN in vitro. Finally, and most
significantly, when RT processivity is measured in a semi-
quantitative polymerase chain reaction (PCR) assay in vivo,
L-CA, the most potent DCTA reported to date, has no
inhibitory effect on either the amount of primed RNA that
entered the cell or on reverse transcription (McDougall et al.,
1998). These data suggest that L-CA and its analogues have
no effect on virus binding, entry, or reverse transcription.
To better understand the in vivo target of L-CA activity,
an L-CA-resistant variant of HIV was selected by culturing
an infectious molecular clone of HIV, HIVNL4-3, in H9 cells
with increasing concentrations of L-CA. The choice of H9
cells is critical as they are a CD4+ transformed cell line
without transforming retroviruses. IN from the resultant
virus contained a single point mutation at glycine 140, a
mutation to serine. This mutation, found in 7 of 10 clones,
confers approximately fivefold resistance for the protein in
biochemical assays (King et al., 2003) and nearly complete
resistance to L-CA in tissue culture (King and Robinson,
1998). When IN from L-CA-sensitive HIV is replaced by IN
containing the G140 to S mutation, the virus retains little
susceptibility to L-CA (King and Robinson, 1998). The
mutation at G140 confers resistance to other DCTA ana-
logues, thus demonstrating that L-CA and its analogues act,
at least in part, through inhibition of IN (King et al., 1999).
Moreover, the G140 mutation confers cross-resistance to
another class of IN inhibitor, the diketoacids (King et al.,
2003).
Despite these results, there has been conflicting data
on both the activity of L-CA and its mechanism of action.
Recently, it was reported that L-CA blocked only viral
entry, not integration (Pluymers et al., 2000). However,
several questions were raised by these studies. First, L-
CA-resistant virus was raised in MT-4 cells following
HIV culture in the presence of much higher concentra-
tions of L-CA (Pluymers et al., 2000) than previously
used to generate resistance in H9 cells (King and Rob-
inson, 1998). Resistance to L-CA mapped to the envelope
glycoprotein, not to IN (Pluymers et al., 2000). Moreover,
Fig. 1. D,L-CA enters cells poorly over 4 h. [14C]-D,L-CAwas added to 1 
106 (A) MT-2 cells or (B) H9 cells. At each time point, cells were washed
three times with PBS containing 50 AM L-CA. Each wash and the cell pellet
were added to ScintiVerse II liquid scintillant and the total counts
determined on a h-scintillation counter. The percent cell-associated CA
was calculated based on the total radioactivity in all washes. Results are the
mean of three separate experiments; error bars are one SD.
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tance to L-CA, although the IN protein used to evaluate
susceptibility contained additional mutations at F185
(F185K) and at C280 (C280S). The reference protein
containing these two mutations required approximately
10-fold more L-CA to inhibit the enzyme by 50%
(IC50) (Pluymers et al., 2000) than previously reported
(Robinson et al., 1996a, 1996b). They also could not test
for virological resistance, as the F185K mutation is lethal.
The first part of the studies reported herein will attempt
to reconcile the reported differences in L-CA’s site of
action.
Although L-CA’s in vivo mechanism of action has been
controversial, in vitro L-CA is a sub-micromolar inhibitor of
IN with a 50% inhibitory concentration (IC50) of approxi-
mately 200 nM, making it one of the most potent IN
inhibitors yet discovered (Beale and Robinson, 2000; King
and Robinson, 1998; McDougall et al., 1998; Robinson,
1998a, 1998b; Robinson et al., 1996a, 1996b; Zhu et al.,
1999). The latter studies reported herein elucidate the
mechanism of action of L-CA via steady-state kinetic analy-
ses. Kinetic analyses have proven useful in understanding
HIV enzyme catalysis (Chow and Brown, 1994; Jones et al.,
1992; Tramontano et al., 1998; Zhu et al., 1999), including
identifying the mechanism of action for several enzyme
inhibitors (Althaus et al., 1993a, 1993b; Dotan et al., 1995;
Gulnik et al., 1995; Lin et al., 1995; Pargellis et al., 1994;
Salto et al., 1994; Tramontano et al., 1998; Zhu et al., 1999).
Work from multiple laboratories has demonstrated that IN is
an enzyme. IN can turn over (Dotan et al., 1995; Jones et al.,
1992; Tramontano et al., 1998; Zhu et al., 1999), can
catalyze the reversal of the integration reaction (Chow
et al., 1992; Robinson et al., 1996a), and steady-state kinetic
analysis of end processing has been performed (Bugreev
et al., 2003; Dotan et al., 1995; Jones et al., 1992; Zhu et al.,
1999). Kinetic analysis has played a key role in the study
and development of both HIV RT and PR inhibitors,
including the identification of their respective inhibitory
mechanisms (Althaus et al., 1993a, 1993b; DeVoss et al.,
1994; Furfine et al., 1992; Pargellis et al., 1994). Steady-
state kinetic analyses of IN have identified several competi-
tive inhibitors of the end processing reaction (Bugreev et al.,
2003; Dotan et al., 1995; Jones et al., 1992; Zhu et al.,
1999). Using steady-state kinetic analyses of disintegration
coupled with other biochemical analyses, it will be shown
that L-CA is a noncompetitive but reversible inhibitor of
HIV IN in vitro.Results
Entry of D,L-CA into MT-2 and H9 cells
Time of addition studies had suggested that L-CA entered
cells slowly. As illustrated in Fig. 1, entry of [14C]-D,L-CA
was approximately fourfold better in H9 cells than in MT-2
cells. Nevertheless, in both cell lines, less than 2% of the
radiolabeled compound entered cells over a 4-h period. Entry
Fig. 2. Entry of 14C-D,L-CA is enhanced by blocking groups but inhibited
by unlabeled L-CA. (A) Cells were labeled for 4 h with either [14C]-D,L-CA
or fully blocked [14C]-D,L-CA and washed as described in the legend to Fig.
1. Washes for each experiment showed logarithmic reductions in [14C]-
labeled compounds with each wash. Final wash (50 Al), the control for cell-
associated radioactivity, was also counted. Those results are shown as 50 Al.
Equal amounts of both blocked and free CA were added to each reaction.
The results are from two separate experiments. (B) [14C]-D,L-CA was
incubated for 4 h with 1  106 H9 cells in approximately 3-fold excess L-
CA or 10-fold excess L-TA. Cells were washed in 50 AM L-CA and percent
uptake was calculated (see legend to Fig. 1). To determine reversibility of
the reaction, L-CA was removed from the wash (No L-CA in wash bar).
Results are means of three experiments; error bars are one SD.
Fig. 3. L-CA below 5 AM inhibits HIV integration but does not inhibit HIV
entry into H9 cells. HIV at the indicated concentrations was pre-incubated
with HIVLAI for 1 h before addition of H9 cells. At each time point, 1  106
cells were harvested and lysed for real-time PCR. (A) Minus strand strong
stop DNA was measured using the AA55/M667 primer pair. Results were
quantified using a standard curve generated from 20000 to 2 HIVLAI
chronically infected H9 cells in the cell lysates from 20000 H9 cells. (B) At
the indicated time points, cells were lysed and cDNA quantified using real-
time PCR and the M661/M667 primer pair. Two LTR circle DNA was
quantified using the MH535/MH536 primer pair. The ratio of two LTR
circle DNA was calculated in HIVLAI chronically infected H9 cell
equivalents (as in A). Specifically, the numerator is infected cell equivalents
of two LTR circle DNA and the denominator is infected cell equivalents of
HIV cDNA. Each fraction was then converted to its decimal equivalent and
plotted. The actual percentage of two LTR circle DNA to cDNA by copy
number, using cycle threshold number, is approximately 0.3%. The data are
representative of three independent experiments with similar results.
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24 h (not shown). Cell-associated radioactivity was approxi-
mately 30-fold higher than the retained radioactivity in 50
Al of wash buffer (Fig. 2A), indicating that the compound was
indeed cell-associated, because the total volume of the cell
pellet was 50 Al. Furthermore, if the synthetic precursor of
radiolabeled L-CA, in which the carboxylic acid and phenolic
hydroxyl groups were blocked as methyl carbonate and
diphenylmethyl groups, respectively, entry was improved
sevenfold (Fig. 2A). Entry into H9 cells was inhibited by
excess unlabeled L-CA but not by an equally charged, in-
active precursor molecule, L-tartaric acid (L-TA) (Fig. 2B).
Finally, L-CAwas associated with H9 cells in a stable mannerfollowing 4 h labeling: equal amounts of [14C]-D,L-CA were
cell-associated whether the cells were washed in the presence
or absence of unlabeled L-CA (Fig. 2B). Thus, L-CA indeed
enters cells poorly and entry is blocked by excess L-CA.
Real-time PCR indicates two sites of action for L-CA
H9 cells were infected with HIVLAI in the presence of L-
CA, L-731,988, or no added inhibitor. Next, at 1, 2, 4, 8, 12,
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washed with phosphate-buffered saline (PBS) and lysed in
buffer containing detergent and proteinase K. The whole
cell lysate was subjected to real-time PCR using primer
pairs that amplify HIV minus strand strong stop DNA,
completely reverse transcribed cDNA, or two LTR circle
DNA. Following entry into the nucleus, the viral cDNA can
either be integrated or, if it fails to integrate, one product
that is formed is two LTR circle DNA, likely catalyzed by
host cellular enzymes (Li et al., 2001). Moreover, two LTR
circle DNA is increased when either mutations or drugs that
adversely affect integration are present (see Butler et al.,
2001; Hazuda et al., 2000; King et al., 2003; Lee and
Robinson, 2004 as recent examples). The effects of L-CA
on entry, as indicated by the levels of minus strand strong
stop DNA, are shown in Fig. 3A. Each experiment was
performed three times with similar results. Neither L-CA
(Fig. 3A) nor L-731,988 (not shown) had an effect on entry
at concentrations below 5 AM. The ratio of two LTR circle
DNA to complete cDNA was approximately 2 in the L-CA-
treated cells and 0.2 in the virus controls (Fig. 3B). Note that
these ratios are calculated from infected cell equivalents, not
copy number. When copy number is estimated, based on
cycle threshold number, the actual number of two LTR
circle copies is roughly 0.3% of cDNA, a finding consistent
with results from others (Butler et al., 2001; Hazuda et al.,
2000). For all experiments, the ratio of two LTR circle DNA
to cDNAwas 3-fold to 10-fold higher for L-CA-treated cells
than for control infections (Fig. 3B). The diketoacid, L-
731,988, was a more potent inhibitor of integration than L-
CA as indicated by a higher ratio of two LTR circle DNA to
cDNA (Fig. 3B). When a nested alu-PCR to quantify
integrated HIV cDNA was performed, both 1 AM L-CA, a
concentration that does not affect entry, and 1 AM L-731,988Fig. 4. IN inhibitors prevent integration of proviral DNA. In triplicate tissue
culture flasks, H9 cells were incubated with 1 AM L-CA or L-731,988, and
HIVLAI (left) or HIVLAI was pre-incubated with each inhibitor for 1 h at
37 jC before addition of an equivalent number of H9 cells (Right). At 24 h,
1  106 cells were lysed and integrated HIVLAI was quantified using a
nested Alu PCR reaction (Lee and Robinson, 2004, modified from
O’Doherty et al., 2002). Error bars are one SD. Numbers above each bar are
P values determined by Student’s two-tailed t test assuming equal variance.
1, HIVLAI; 2, HIVLAI and 1 AM L-CA; 3, HIVLAI and 1 AM L-731,988.reduced the levels of integrated DNA by 30–50% (Fig. 4).
When each compound was pre-incubated with HIV, the
effects of both compounds were enhanced (Fig. 4). These
data are consistent with the f1 AM EC50 for both com-
pounds against HIVLAI. The data for L-CA are representa-
tive of two separate experiments performed in triplicate; in
both, L-CA inhibited integration by 30–50%. Thus, at a
concentration of 1 AM, L-CA inhibits integration as mea-
sured by both an increased ratio of two LTR circle DNA to
cDNA and a statistically significant decrease in integrated
HIV cDNA with no affect on HIV entry.
F185K mutation in IN confers resistance to L-CA:
An experimental question to be answered was why a G140
to S mutation within IN was reported to not confer resistance
to L-CA (Pluymers et al., 2000) when we had previously
shown that the G140 to S mutation conferred resistance to L-
CA (King and Robinson, 1998; King et al., 2003), to L-CA
analogues (King et al., 1999), and to L-731,988 (King et al.,
2003). The reference protein used by Pluymers et al. (2000)
contained F185K and C280S mutations, as did the protein
that contained the G140 to S mutation. Pluymers et al. (2000)
reported that the IC50 for both proteins were approximately 2
AM, a log10 higher than previously reported for L-CA (Rob-
inson et al., 1996a, 1996b). We thus determined the IC50 of L-
CA against both IN from HIVNL4-3 and IN containing the
F185K mutation (INF185K). The IC50 of L-CA against the
reference IN at a protein concentration of 150 nM was 593F
293 nM. The IC50 of L-CA against INF185K at a protein
concentration of 500 nM was 5.3 F 0.66 AM ( P <
0.000005). The different protein concentrations were based
on different catalytic activities of the two proteins: it required
approximately threefold more INF185K to catalyze the disin-
tegration reaction than IN from HIVNL4-3. Nevertheless, the
same result was found if the two proteins were tested at equal
protein concentrations rather than equal protein activities
(data not shown). Thus, the F185K mutation confers signif-
icant resistance to L-CA, likely masking the resistant pheno-
type of the G140 to S mutation.
Steady-state kinetic analysis of IN
Having confirmed that L-CA is an inhibitor of HIV
integration in tissue culture, steady-state kinetic analysis
of disintegration was next used to determine the bioche-
mical mechanism of IN inhibition by L-CA. Although
steady-state analyses of end processing have been per-
formed by several groups (Bugreev et al., 2003; Dotan
et al., 1995; Jones et al., 1992; Zhu et al., 1999), it has
been suggested that IN aggregates in vitro under reaction
conditions (van Gent et al., 1991). Indeed it was concluded
that IN is likely never free in solution and instead rapidly
binds nonspecifically to the DNA substrate, slowly cuts the
viral DNA, and remains bound to the target DNA after end
processing (van Gent et al., 1991). To determine if this was
Fig. 5. Integration substrates and products are primarily found in the soluble fraction. (A) Disintegration reaction substrate and products. (B) End processing/
strand transfer substrate and products. Reactions were performed by addition of substrate and reaction buffer to 25 nM IN, unless otherwise indicated, at
various times and incubated at 30 jC. Reactions were centrifuged at 10000 g for 5 min unless otherwise indicated. All reactions were stopped by the addition
of 18 mM EDTA. (C) Representative disintegration assays. db-Y1 (500 nM) was added to each reaction. (1) Substrate alone; IN and substrate for (2) 0 min; (3)
4 min; (4) 8 min; (5) 12 min; (6) 16 min; (7) 24 min; (8) 36 min; or (9) 60 min. Additional controls included (10) 300 nM IN and substrate for 60 min
precipitated with TCA; (11) 100 nM IN and substrate for 60 min precipitated with TCA; (12) 300 nM IN and substrate for 60 min; and (13) pellet from 25 nM
IN and substrate for 60 min precipitated with TCA. (D) Representative end processing/strand transfer reactions. All reactions contained 0.05 pmol V1/V2
substrate. (1) Substrate alone; IN and substrate for (2) 0 min; (3) 4 min; (4) 8 min; (5) 12 min; (6) 16 min; (7) 24 min; (8) 36 min; or (9) 60 min. Additional
controls included (10) 25 nM IN and substrate for 60 min precipitated with TCA; (11) 300 nM IN and substrate for 60 min centrifuged for 5 min; or (12)
centrifuged for 30 min, (13) pellet from 300 nM IN and substrate for 60 min precipitated with TCA. For all lanes, S = supernatant; P = pellet; * = substrate;
arrow = disintegration product; 2 = strand transfer product; S.T.P. = strand transfer products.
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viously published were carried out. The disintegration
(Fig. 5A) and end processing (Fig. 5B) reactions are
illustrated. Reactions were carried out from 4 to 60 min at
30 or 37 jC. The reactions were stopped with EDTA,
centrifuged for 5 min or 30 min at 10000  g, and the
supernatants and pellets were separated by denaturing
polyacrylamide gel electrophoresis (PAGE). Very little of
the reaction products from either the disintegration (Fig. 5C)
or end processing reactions (Fig. 5D) were observed in the
pellet at any time, regardless of the length of time the
reactions were performed or the length of time of the
centrifugation. Precipitation of the reactions with trichloroa-
cetic acid (TCA) did increase the amount of product in the
pellet, but only slightly. It is also clear that strand transfer
can be detected as early as 4 min into the reaction (Fig. 5D,
lanes marked 3), making it unlikely that the processed ends
are bound by IN for any significant length of time. van Gent
et al. (1991) did not report any strand transfer products in
their reactions. Finally, when detergent was removed from
the reaction, results similar to those observed in the presence
of detergent were obtained (not shown). Thus, steady-state
kinetic analyses can be performed for HIV-1 IN under the
conditions employed in these studies.As previously stated, the disintegration substrate is ideal
for Michaelis–Menten kinetic analyses because only one
substrate and one product exist. The db-Y1 disintegration
substrate and reaction are illustrated in Figs. 5A and 6.
Kinetic reactions were performed in substrate excess and at
initial velocities: times approaching zero and less than 20%
product conversion. An example is shown in Fig. 6B. To
determine whether kinetic analysis is a valid method for
examining the mechanism of IN inhibition, kinetic reactions
were performed in the presence or absence of a putative
noncompetitive inhibitor, EDTA, and a competitive inhibi-
tor, unlabeled 3V-end processing substrate. Fig. 6 shows that
the competitive and noncompetitive relationships hold true
in kinetic analyses. EDTA (Fig. 6C) is a noncompetitive or
irreversible inhibitor of IN. The Lineweaver–Burk plot
(Fig. 6C) reveals that addition of EDTA leads to a signi-
ficant decrease in Vmax (P = 0.01) without significant
changes in Km (P = 0.7) at 8 mM. 3V-Azido, 3V-deoxythy-
midine monophosphate (AZT-MP) (not shown) showed
similar results with a change in Vmax (P = 0.02) but no
change in Km (P = 0.9) at 1 mM. In contrast, the Line-
weaver–Burk plot for the unlabeled V1/V2 substrate
resulted in an increase in Km (P = 0.005) without a
significant change in Vmax (P = 0.05) at 100 nM,
Fig. 6. The disintegration reaction and Lineweaver–Burk plots of IN with inhibitors. In panel A, the disintegration reaction using the db-Y1 substrate is
illustrated. IN catalyzes the reversal of the integration reaction, resulting in the conversion of a 38 mer oligonucleotide into 32P-labeled 14 mer and an unlabeled
24 mer. Panel B, a representative disintegration kinetic gel, used to calculate velocities for steady-state kinetic analyses. The time of the reactions, in minutes,
are shown above the gel. Each reaction was performed in duplicate and the product was separated from the substrate by denaturing PAGE. Duplicate samples
were loaded on adjacent lanes on the gel. For all times, substrate concentrations are 1, 100 nM; 2, 175 nM; 3, 250 nM; 4, 325 nM; 5, 400 nM; and 6, 500 nM.
Panel C, double reciprocal plot of kinetic reactions containing IN and H2O (.), 7 mM EDTA (o), or 8 mM EDTA (z). Each point is the mean of two or three
experiments performed in duplicate (four or six total replicates). Panel D, a double reciprocal plot of kinetic reactions containing IN + H2O (.), IN + 50 nM
unlabeled V1/V2 (o), or IN + 100 nM unlabeled V1/V2 (z). The results are means of three experiments in duplicate (six total replicates). For panels B–D,
kinetic reactions were performed using 25 nM recombinant IN and excess db-Y1 substrate at 37 jC; error bars are one SD.
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inhibitor (Fig. 6D). These data are similar to those published
for Moloney murine leukemia virus and HIV (Dotan et al.,
1995; Zhu et al., 1999) in the 3V-end processing reaction.
Moreover, the Km for the db-Y1 substrate, 140 nM, is
identical to that previously reported (Chow and Brown,
1994). For all statistical analyses, significance was consid-
ered below P = 0.05 using Student’s two-tailed t test. The
Vmax and Km calculated from all reactions are illustrated in
Table 1.
L-CA is a noncompetitive or irreversible inhibitor of IN
To determine the mechanism by which L-CA exerts its
inhibitory effects on IN, steady-state kinetic analyses were
performed in the presence or absence of L-CA. L-TA was
used as a negative control. Addition of L-TA did notsignificantly alter the kinetic profile of IN (Fig. 7A) as
neither the Vmax (P = 0.63) nor the Km (P = 0.9) differ from
IN alone. Addition of L-CA, however, results in a decrease
in Vmax (P = 1.8  105) without altering the Km (P = 0.59)
(Fig. 7B). Furthermore, increasing concentrations of L-CA
led to decreasing Vmax without affecting Km (Fig. 7B). Thus,
L-CA is working through a noncompetitive or irreversible
mechanism of inhibition.
L-CA is a tight-binding inhibitor of IN
Inhibitors that bind tightly to their enzyme targets mani-
fest a pattern of noncompetitive or irreversible inhibition in
steady-state kinetic analyses, regardless of their actual
mechanism of inhibition. This is due primarily to the slow
off rate, which can result in a condition in which inhibitor
binding is not at equilibrium with the enzyme under initial
Table 1
Kinetic values for IN in the presence and absence of IN inhibitors
Inhibitor Mean Vmax
a P valueb Mean Km
c P valueb
Noned 4.4  103 – 140 –
L-TA (500 nM) 4.7  103 0.63 164 0.9
L-CA (300 nM) 2.3  103 1.8  105 152 0.59
Nonee 7.4  103 – 140 –
EDTA (8 mM) 2.5  103 0.01 218 0.07
AZTMP (1 mM)f 2.1  103 0.02 262 0.90
V1/V2 DNA (50 nM) 9.0  103 0.13 322 0.04
V1/V2 DNA (100 nM) 1.3  102 0.05 703 0.005
a Vmax units are mole disintegration product per minute per mole IN.
b P values were determined using Student’s two-tailed t test assuming equal
variances.
c Km units are nM dBY1.
d Untreated control for L-TA, L-CA inhibition experiments.
e Untreated control for EDTA, AZTMP, and V1/V2 DNA inhibition
experiments.
f Means and statistical analysis are based on a duplicate of duplicates.
Fig. 7. L-CA is a noncompetitive inhibitor of IN by steady-state kinetic
analyses. Kinetic reactions were performed using 25 nM recombinant IN
and excess db-Y1 substrate at 37 jC. (A) Double reciprocal plot of kinetic
reactions containing IN in the presence and absence of L-CA. The results
are means of three experiments in duplicate (six total replicates) o = IN +
H2O, . = IN + 500 nM L-TA, z = IN + 300 nM L-CA. Error bars are one
SD. (B) Increasing concentrations of L-CA were used as an inhibitor in
steady-state kinetic analyses. Concentrations are given to the right of each
line; the points are the means of duplicate reactions.
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inhibitors have been documented (Williams and Morrison,
1979), and the data for L-CA indicate a possible tight-
binding interaction. Specifically, the double reciprocal plot
from the L-CA kinetic experiment exhibits a downward
curvature at high inhibitor and high substrate concentrations
(NB: 600 nM L-CA in Fig. 7B), which is characteristic of
many tight-binding inhibitors (Williams and Morrison,
1979). The reported IC50 for L-CA, 150 nM, is within 10-
fold of the protein concentration used for the assay, suggest-
ing a stoichiometric interaction. Using the initial velocity
data from the kinetic experiments and kinetic equations
(Williams and Morrison, 1979), the Ki for L-CA was
calculated to be between 250 and 350 nM, suggesting that
the interaction between IN and L-CA might not be at
equilibrium under the initial velocity conditions employed
in the steady-state kinetic assay. Finally, the IC50 of L-CA
was determined at a fixed enzyme concentration in the
presence of increasing substrate concentrations (Williams
and Morrison, 1979). No significant change in IC50 was
observed over a 1.5 log10 range of substrate concentrations
tested (Fig. 8), indicating a noncompetitive or irreversible
interaction between L-CA and HIV IN.
L-CA interacts in a noncovalent manner with IN
Previous studies using membrane dialysis and the end
processing substrate had identified L-CA as an irreversible
inhibitor of IN (Zhu et al., 1999). To better understand the
nature of the inhibition of IN by L-CA, equilibrium dialysis
was performed. However, control experiments showed that
L-CA did not dialyze to equilibrium after 24 h (not shown).
Therefore, to examine the possibility that L-CA forms a
covalent interaction with IN, both the recombinant IN core
(amino acids 50–212) and full-length IN were incubated,
individually, with the inhibitor under reaction conditions for
30 min. The proteins were denatured and resolved by
sodium dodecylsulfate PAGE (SDS-PAGE) followed bystaining with Coomassie blue. Band migration of neither
full-length IN nor the core was altered by the addition of L-
CA, suggesting a noncovalent interaction (not shown).
As an additional confirmation that L-CA binding is non-
covalent, IN was incubated with 14C-D,L-CA or fully
blocked 14C-D,L-CA for 1 h at 37 jC under identical
conditions to those that result in complete inhibition of
end processing by L-CA (200 pmol L-CA and 4 pmol IN).
The proteins were denatured and separated by SDS-PAGE.
Following Coomassie staining, the protein bands were cut
out of the gel and radioactivity was determined by liquid
scintillation counting. Background counts were 20–50 cpm,
the radioactivity of inhibitor added to the reaction was
16000 cpm; the radioactivity in the band was at background
Fig. 8. IC50 analysis of L-CA with increasing concentrations of
disintegration substrate. IN (100 nM) was incubated with L-CA at
concentrations ranging from 0.03 to 10 AM and with increasing amounts
of Y-oligo substrate from 5 to 155 nM for 1 h at 37 jC. IC50’s were
calculated using Calcusyn software and plotted. The solid line represents
the linear regression of plotted points. Each point represents the mean from
a minimum of three IC50’s with error bars representing one SD.
Fig. 9. IN disintegration activity after successive washes. IN was incubated
with either H2O (1), L-TA (2), or (3) L-CA followed by a series of six
centrifugational washes with buffer (4). L-CA alone was washed once and
both the retentate (5) and flow-through (6) were analyzed in the
disintegration assay. L-CA was incubated with HEL, then washed once
and the flow through analyzed in the disintegration assay (7). Bars are the
mean percent product of a minimum of three replicates with error bars
representing one SD.
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of 300 cpm of compound could be bound if the IN-L-CA
interaction were stoichiometric. The experiments were thus
repeated with five times as much IN and five times as much
L-CA. The mean amount of radioactive compound added to
each reaction was 64347 cpm with one SD of 10170 cpm.
Given 1:1 binding of IN by L-CA, it is calculated that
approximately 1300 cpm would be bound to IN. Again,
radioactivity in the band was at background levels. Thus, by
two different SDS-PAGE analyses, the radioactive molecule
was not covalently joined to the protein.
L-CA inhibition of IN is reversible
Because results from the SDS-PAGE experiments sug-
gested a noncovalent interaction between L-CA and IN, a
series of washing experiments were performed utilizing
centrifugal filtration devices. The filtration devices had a
10000 Da cutoff; therefore, the IN protein (32 kDa) would
be retained although the buffer and inhibitor would flow
through the column. IN, with or without L-CA, was con-
centrated by centrifugation and then rediluted, effectively
washing the recombinant protein. Analysis of either the
retentate or the flow-through from a variety of control
reactions was performed to determine whether L-CA was
retained in the column. Analysis of a single wash of L-CA
alone, followed by analysis of both retentate and flow-
through, showed that only the flow-through inhibited IN
(Fig. 9). Therefore, unlike the dialysis membrane, L-CA
could freely pass through the filter membrane. Analysis of
the retentate from a reaction in which IN was incubated with
L-TA and subjected to six washings resulted in no inhibition
of disintegration activity compared to washed IN alone (Fig.
9). L-CA in the presence of hen egg lysozyme (HEL) waswashed once and the flow through analyzed for inhibition of
IN. The flow-through inhibited IN to a similar extent to that
of L-CA alone, demonstrating that L-CA is not a nonspecific
protein-binding agent (Fig. 9).
Following these control reactions, IN was incubated with
L-CA at the IC90, then subjected to 6, 8, or 10 washes with
storage buffer and the retentates analyzed for IN activity in
both 3V-end processing and disintegration reactions (Fig.
10). IN was found to progressively lose activity over the 10
washes in both disintegration and 3V-end processing reac-
tions (Fig. 10). Nevertheless, washing of IN and L-CA
samples resulted in partial recovery of IN activity in all
samples tested, with maximal recovery after eight washes
for both 3V-end processing and disintegration reactions.
Recovery of enzyme activity was most prominent in the
disintegration reaction (Figs. 10A and C). The percent
inhibition of IN was 47% after eight washes compared with
90% for the unwashed protein; thus, L-CA inhibition was
reversible. These experiments were repeated three times
with similar results. If the L-CA–IN interaction were irre-
versible, no amount of washing would have resulted in
recovery of IN enzymatic activity.
Because activity was lost following repeated washing
(Fig. 10), IN could have been lost in the membrane,
denatured, or subject to proteolysis. The latter, proteolysis,
was concerning as it was possible, though unlikely, that the
reversibility of the reaction was secondary to cleavage of L-
CA from the protein. As illustrated in Fig. 11A, eight
washes led to loss of protein, probably secondary to binding
by the membranes. However, there was no evidence of
proteolysis. When the protein was specifically cleaved by
trypsin (Fig. 11B), a smaller fragment could be detected. No
proteolytic cleavage products of any size were present in
Fig. 10. L-CA inhibition of HIV IN disintegration and integration activities is reversible. IN was incubated in the presence (IN + L-CA) or absence (IN + H2O)
of L-CA and subjected to a series of 6, 8, or 10 washes (6, 8, or 10, respectively). Positive controls of L-CAwith no washing (0x) are also shown. (A) An
aliquot from each wash was analyzed in triplicate in the disintegration reaction using the dumbbell substrate. Black arrow is substrate; gray arrow is
disintegration product. (B) An aliquot from each wash was analyzed in triplicate using the 3V-end processing and strand transfer reaction. Black arrow is
substrate; gray arrow is 2 product; gray bracket identified as S.T.P indicates strand transfer products. C and D show the mean percent conversion from each
triplicate reaction with error bars representing one SD. (C) Disintegration reaction; (D) 3V-end processing reaction.
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ments were not generated during the washing experiments.Discussion
Arguably, before 2000, the most promising lead class of
inhibitors of HIV IN had been the DCQAs and theirFig. 11. SDS-PAGE analysis of HIV IN after washing. (A) HIV IN was
either loaded into SDS-PAGE running buffer (lane 2) or washed 6 (lane 3),
8 (lane 4), or 10 (lane 5) times as described for Fig. 10. Lane 1 is the size
marker; the arrow is IN. Size markers are 49.5, 37.4, and 26 kDa. (B) IN
was added to SDS-PAGE running buffer (lane 1), digested for 15 min with
trypsin (lane 3), or washed (Lane 4) as described in the legend to Fig. 10.
Lane 2 is the size marker from top to bottom: 46, 29, 20 kDa. For all panels,
washing experiments were performed using a protein concentration column
(Pall Corporation).analogues. More recently, the identification of the diketo-
acid IN inhibitors (Espeseth et al., 2000; Hazuda et al.,
2000) has advanced the field. DCQAs, like most bis-
catechols, inhibit catalysis, both 3V-end processing and
disintegration, as well as strand transfer (Robinson et al.,
1996a). The diketoacids specifically inhibit strand transfer
(Espeseth et al., 2000; Hazuda et al., 2000). Understanding
how each molecule interacts with IN and its catalytic site are
critical to future drug discovery efforts. Unfortunately,
questions surrounding the mechanism of action of L-CA
and its analogues in tissue culture have hindered such
studies.
The experiments reported herein clarify the in vivo
mechanism of action for L-CA. Previous results in which
a variant of HIV resistant to L-CA was raised suggested that
L-CA was acting, at least in part, through inhibition of IN
(King and Robinson, 1998). However, sub-allelic recon-
struction, although demonstrating that a glycine 140 to
serine mutation within IN confers resistance to L-CA, also
demonstrated that another site of action may be involved.
Specifically, some residual susceptibility to L-CA was
detected in the virus containing only the G140 to S mutation
(King and Robinson, 1998). In a recent report, Pluymers
et al. (2000) have identified the additional site as being HIV
R.A. Reinke et al. / Virology 326 (2004) 203–219 213entry. L-CA clearly affects viral entry at concentrations of
5 AM and higher (Fig. 3A). However, L-CA also inhibits
integration as indicated both by an increased ratio of two
LTR circle DNA to cDNA (Fig. 3B) and an accompanying
decrease in integrated provirus (Fig. 4). The EC50 of L-CA
against HIV is approximately 500 nM (Reinke et al., 2001),
a concentration that does not inhibit HIV entry in H9 cells
(Fig. 4A). This supports the finding that L-CA inhibits IN
preferentially, as even 500 nM L-CA increases the ratio of
two LTR circle DNA to cDNA in H9 cells (Fig. 3B). Thus,
the question of whether L-CA inhibits integration appears to
be answered. A question that arises is, ‘‘how to improve
entry of L-CA into cells and thus improve its anti-IN
effects?’’
Pluymers et al. (2000) concluded that a G140 to S
mutation within IN did not confer resistance to L-CA based
on in vitro enzymatic data for a protein that contained C280
to S and F185 to K mutations in addition to the G140 to S
substitution. The data reported herein indicate that the
F185K mutation confers approximately 10-fold resistance
to L-CA. Hazuda et al. (1997) have previously shown that
bis-catechols such as L-CA inhibit assembly of IN onto the
cDNA ends. The F185K mutation is believed to prevent
proper assembly of higher order IN complexes and thus
prevents particle assembly (Engelman et al., 1997; Wu et al.,
1999). Moreover, bis-catechols do not inhibit pre-integra-
tion complexes if IN is already assembled on the viral
cDNA ends (Farnet et al., 1998). Thus, the F185K mutation
may confer resistance to L-CA if L-CA inhibits the assembly
of higher order IN complexes. Indeed, the F185K resistance
to L-CA complements recently published data indicating
that IN containing the F185K and C280S mutations is
resistant to several diketoacid IN inhibitors (Marchand
et al., 2003).
The use of 14C-D,L-CA indicates that less than 2% of CA
enters cells in 4 h (Fig. 1). Moreover, H9 cells demonstrate
improved entry compared to MT-2 cells; perhaps the same
holds true for the MT-4 cells used by Pluymers et al. to
select for resistance to L-CA. Regardless, blocked CA
showed much greater entry into H9 cells over the same
time period (Fig. 2). Therefore, synthesis of L-CA ana-
logues in which the catechol and carboxylic acid groups are
blocked with labile groups might increase the activity of L-
CA against HIV IN. Analogues with improved selectivity
for IN over entry have already been synthesized (Reinke et
al., 2002). A combination of approaches including im-
proved formulations of L-CAwith increased entry, synthesis
of analogues with improved entry, and a search for pro-
drugs with improved entry and selectivity for IN are critical
to the development of clinically useful DCTAs and
DCQAs.
The data provided here elucidate the in vitro bioche-
mical mechanism of action of L-CA. Steady-state kinetic
analysis along with washing experiments and tight-bind-
ing inhibitor analyses were performed to characterize the
in vitro mechanisms by which L-CA interacts with IN.Previous work from others (Dotan et al., 1995; Jones
et al., 1992; Zhu et al., 1999) and our laboratory (King
et al., 2003) demonstrate the utility of steady-state kine-
tics in the evaluation of IN inhibitors and IN proteins.
EDTA and unlabeled substrate were employed as controls,
demonstrating patterns of noncompetitive and competitive
inhibition, respectively (Fig. 6). HIV IN utilizes divalent
metal cations for the polynucleotide transfer reaction
(Carteau et al., 1997; Hazuda et al., 1997; Lee and
Han, 1996; Lee et al., 1995); therefore, by stripping the
protein of metal, the enzymatic reactions should be
inhibited, although EDTA itself will not compete for the
active site. Thus, the velocity of the reaction should be
affected, but because the substrate can still interact with
the active site, a noncompetitive pattern will be observed
on double reciprocal plots. Such a pattern was observed
(Fig. 6). In contrast to this, the unlabeled V1/V2 substrate
should enter the binding site and compete with labeled
substrate. The 3V-end processing substrate was chosen as
the competitive inhibitor because it has a slower turnover
rate than the db-Y1 substrate, thus enhancing the ob-
served inhibitory effect and making the competitive
mechanism clear. The 3V-end processing substrate has
previously been shown to be a competitive inhibitor of
Moloney murine leukemia virus IN (Dotan et al., 1995).
Crystal structures of the core region of IN, along with
mutagenesis data, suggest that a single active site cata-
lyzes the polynucleotidal transfer reaction for 3V-end
processing, strand transfer, and disintegration (Bujacz
et al., 1996a, 1996b; Dotan et al., 1995; Engelman and
Craigie, 1992; Engelman et al., 1997; Goldgur et al.,
1998). The unlabeled substrate thus competes with the
labeled db-Y1 for access to the active site, resulting in
larger amounts of labeled substrate required to achieve the
same velocity. 3V-End processing substrate should, and
does, change the Km without changing the Vmax, resulting
in the classical profile of a competitive inhibitor (Fig. 6).
Herein we show that L-CA is a noncompetitive, tight-
binding inhibitor of IN. Its binding is neither dependent
upon nor competitive with DNA substrate. Unlike L-CA,
L-731,988 is a competitive inhibitor and its binding to IN
inhibits subsequent binding of DNA substrate (Espeseth et
al., 2000). Moreover, we confirm that steady-state kinetic
analyses of IN can be a powerful tool to determine the
mechanism of action of any inhibitor. The linear double
reciprocal plots, significant levels of product as early as 4
min, ability to discern different mechanisms of action for
inhibitors according to their classic definitions, reproduc-
ibility of Km for a substrate when compared to the
published literature, small standard deviations across mul-
tiple reactions, and lack of aggregation in the reactions all
demonstrate that IN, at least in the disintegration reaction,
obeys Michaelis–Menten kinetics.
The mechanism by which L-CA, the diketoacids, and
other inhibitors of IN inhibit the IN protein will become
increasingly important now that the first IN inhibitors
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that IN inhibitors can be studied using steady-state kinetic
analysis, the foundation has been laid for studies on both
different classes of IN inhibitor and on drug-resistant, as
well as drug-sensitive, IN proteins. Elucidating the mech-
anism of action for IN inhibitors may prove paramount to
the development of new classes of inhibitors for clinical
use and also to determine how cross-resistance to diffe-
rent classes of IN inhibitors can occur. It would appear
from the results presented herein, coupled with the find-
ings that resistance to L-CA confers cross-resistance to
diketoacid IN inhibitors (King and Robinson, 1998; King
et al., 2003) and, conversely, that resistance to diketoacid
IN inhibitors confers cross-resistance to L-CA (Lee and
Robinson, 2004), that L-CA is an in vivo inhibitor of
integration.Materials and methods
Uptake of radiolabeled CA
Compounds
AZT-MP and EDTA were purchased from Sigma Com-
pany. The diketoacid, L-731,988 (Hazuda et al., 2000), was
synthesized as described (Selnick et al., 1999). L-CA was
synthesized; its purity and chemical properties have been
described previously (Beale and Robinson, 2000; King and
Robinson, 1998; McDougall et al., 1998; Robinson, 1998a,
1998b; Robinson et al., 1996a, 1996b; Zhu et al., 1999).
1,4-14C-D,L-CA was synthesized from 1,4-14C-D,L-TA
(American Radiolabeled Chemicals, Inc., St. Louis, MO)
(Buhler et al., 1963), essentially as described previously for
unlabeled L-CA (King et al., 1999). The final product was
purified by preparative high-pressure liquid chromatography
to remove impurities and separate the coproduct, meso-
chicoric acid, from the mixture. The specific activity of the
final compound was 102 mCi/mmol.
Uptake of radiolabeled CA
In a final volume of 50 Al, 1  106 H9 or MT-2 cells
were incubated with 1 mM 14C-D,L-CA for various times
between 1 and 4 h at 37 jC. This concentration of CA
was chosen as it was the lowest concentration that could
be readily and reproducibly quantified in the cell pellet by
scintillation counting. In some experiments, the cells were
incubated with 14C-D,L-CA and excess cold L-CA or L-TA.
Cells were washed three times with PBS containing 50
AM unlabeled L-CA. Each wash and the cell pellet were
separately added to 3.5 ml of ScintiVerse II liquid
scintillant. The scintillant was allowed to quench over-
night in the dark and was counted for 10 min on a
Beckman liquid scintillation counter. The percent of CA
taken up by cells was calculated as the ratio of cpm in the
cell pellet to the total cpm in the three washes and the cell
pellet times 100.In vivo mechanism of anti-HIV activity by L-CA by real-time
PCR
Infection conditions for real-time PCR
HIVLAI from infected H9 cells was incubated for 1 h at
37 jC with 0, 0.5, 1, 5, or 10 AM L-CA or 10 AM L-731,988.
Next, H9 cells were added; the final multiplicity of infection
was less than one. At each time point, beginning at 1 h post-
inoculation, cells were removed, washed, and 1.0  106
cells were lysed using a PCR lysis buffer containing
proteinase K (Kellogg and Kwok, 1990) as described
previously (King et al., 2003; Reinke et al., 2002; Victoria
et al., 2003). At 24, 48, and 72 h post-inoculation, cells were
also monitored by indirect immunofluorescence assay using
polyclonal human anti-HIV immunoglobulin as described
previously (Robinson et al., 1989). Immunofluorescence
results supported the real-time PCR data in that all com-
pounds exhibited anti-HIV activity at the concentrations
used (data not shown).
Real-time PCR oligonucleotide primers
AA55: 5V-CTGCTAGAGATTTTCCACACTGAC-3V
(HIV-1LAI anti-sense 635–612)









Real-time PCR cycle conditions
Real-time PCR was performed using the Cepheid
Smart CyclerR (Fisher Scientific, Tustin, CA) and SYBR
Green I (Sigma-Aldrich or Molecular Probes). PCR con-
ditions for quantifying products of reverse transcription
have been reported previously (King et al., 2003; Reinke
et al., 2002; Victoria et al., 2003). HIV-1-specific primers
pairs were used to detect minus strand strong stop DNA,
AA55/M667 (Zack et al., 1990), and completely synthe-
sized HIV cDNA, M661/M667 (Zack et al., 1990). For
two LTR circle DNA, the MH535/MH536 primer pair
was used (Butler et al., 2001) as described previously
(King et al., 2003; Reinke et al., 2002; Victoria et al.,
2003).
Nested alu-PCR to quantify integrated HIV cDNA
To quantify integrated HIV DNA (provirus), a modi-
fication of a nested alu PCR reaction first described by
O’Doherty et al. (2002) was performed. DNA from each
standard and each cell lysate sample were first amplified
with alu (Butler et al., 2001) and M661 (Zack et al.,
1990) primers. PCR conditions were initial denaturation at
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s, 63.8 jC for 30 s, and 72 jC for 1 min 15 s. The
resulting PCR product was diluted in an equal volume of
H9 cell lysate (106 cells/ml) and 2 Al of this diluted PCR
product was amplified in the presence of SYBR green-I
using the AA55 and M667 primers as described, previ-
ously (King et al., 2003; Reinke et al., 2002; Victoria et
al., 2003).
Enzyme analysis: biochemical mechanism of action for
L-CA
Oligonucleotide substrates for integration reactions
Oligonucleotides were synthesized by Sigma/GenoSys
(The Woodlands, TX).
db-Y1 (38 mer): 5V-TGCTAGTTCTAGCAGGCCCTTG-
GGCCGGCGCTTGCGCC-3V
V1 (21 mer): 5V-ATGTGGAAAATCTCTAGCAGT-3V
V2 (21 mer): 5V-ACTGCTAGAGATTTTCCACAT-3V
T1 (16 mer): 5V-CAGCAACGCAAGCTTG-3V
T3 (30 mer): 5V-GTCGACCTGCAGCCCAAGCTTGC-
GTTGCTG-3V
V2 (21 mer): 5V-ACTGCTAGAGATTTTCCACAT-3V
V1/T2 (33 mer): 5V-ATGTGGAAAATCTCTAGCAGG-
CTGCAGGTCGAC-3V
The db-Y1, V1, and V2 oligomers were gel purified as
described previously (Chow, 1997; King and Robinson,
1998; King et al., 1999). Oligonucleotide substrates (db-
Y1, V1, and T1) were labeled at the 5V-end using T4
polynucleotide kinase (Gibco Invitrogen Corporation,
Carlsbad, CA) and [g-32P] ATP (3000 Ci/mmol, Amer-
sham Biosciences, Piscataway, NJ). The labeled oligonu-
cleotide was purified using P6 MicroBiospin columns
(BioRad Laboratories, Hercules, CA) and eluted in TEN
buffer (10 mM Tris–HCl, pH 8.0, 1 mM EDTA, pH 8.0,
0.1 M NaCl). The db-Y1, V1/V2, and Y oligomer (T1,
T3, V2, and V1/V2) substrates were annealed as de-
scribed previously (King and Robinson, 1998; King et
al., 1999) to generate labeled, double-stranded substrate
molecules.
Purification of recombinant IN
IN fused to a six histidine tag was affinity purified
from Escherichia coli using Ni2+ column chromatography
as described previously (King and Robinson, 1998; King
et al., 1999; Reinke et al., 2001). The fraction containing
IN at greater than 90% purity, as assessed by SDS-
PAGE followed by Coomassie blue staining, was dia-
lyzed into storage buffer {20 mM N-[2-hydroxyethyl]pi-
perazine-NV-[2-ethanesulfonic acid] (HEPES), pH 7.5, 0.1
mM EDTA, 10 mM dithiothreitol (DTT), 0.3 M NaCl,
10 mM 3-[(cholamidopropyl)dimethylammonio]-1-pro-
pane-sulfonate (CHAPS), and 20% glycerol} for use in
in vitro assays.IC50 analyses
The susceptibility of IN to inhibition by L-731,988 and L-
CA was performed as described previously (King et al.,
1999, 2003; Reinke et al., 2002; Robinson et al., 1996a,
1996b). Briefly, gel purified and 32P-labeled db-Y1 was
incubated with recombinant HIV-1 IN and inhibitor at
concentrations between 30 nM and 10 AM in reactions
performed in triplicate. The final volume of the reactions
was 20 Al. The reactions were allowed to proceed for 1 h at
37 jC. Reactions were stopped by addition of EDTA to a
final concentration of 18 mM. Products were separated from
substrates by 15% denaturing PAGE. The percent conver-
sion of substrate to product was calculated by phosphor-
imager analysis. The IC50’s were computed using Calcusyn
for Windows software.
Kinetic analysis of the disintegration reaction
The disintegration reaction was performed as described
(Charlton, 1998; Chow, 1997; Chow et al., 1992), with the
following modifications: Reactions were performed in tripli-
cate in the presence or absence of inhibitor and 25 nM
recombinant IN. Reactions were started in 30-s increments
by the addition of db-Y1 oligonucleotide, diluted to 80 Al in
TEN, resulting in final db-Y1 substrate concentrations of
100, 175, 250, 325, 400, or 500 nM. Reactions were per-
formed at 37 jC. Under these reaction conditions, substrate
was in excess of IN at all substrate concentrations tested. For
some kinetic experiments, 20 Al was removed from each
reaction at 4, 8, and 12min and added to 2 Al of ice-cold 0.2M
EDTA (18 mM final) and placed on ice. For kinetic analysis
using L-CA at multiple concentrations, samples were re-
moved at 8, 12, and 16 min. Following the collection of all
time points, 7 Al of gel-loading buffer (98% deionized
formamide, 10 mM EDTA, pH 8.0, 0.05% bromophenol
blue, 0.05% xylene cyanol) was added to each tube. Reaction
products were resolved on 15% denaturing PAGE with 7 M
urea in 1 Tris–borate–EDTA (TBE) buffer. Gels were
subsequently dried and quantitated on a Storm 860 Phosphor-
Imager (Molecular Dynamics, Sunnyvale, CA) using the
ImageQuant software package (Molecular Dynamics). Initial
velocities of IN in the presence of each substrate concentra-
tion were defined as the slope of the progress curve (moles
product per minute) at each substrate concentration. Double
reciprocal plots (Lineweaver–Burk analysis) were plotted for
the mean of each initial velocity at each substrate concentra-
tion. Linear regression analysis was calculated using Sigma
Plot. The Vmax and Km were calculated as the inverse of the y
intercept and x intercept, respectively. Both values were
confirmed using Microsoft Excel. Each reaction was per-
formed a minimum of three times in duplicate. Statistical
significance for Vmax and Km were determined using Stu-
dent’s two-tailed t test assuming equal variance.
Pelleting of IN reactions
Either db-Y1 or V1/V2 substrate was added to kinetic
reactions as described above. After incubation for the
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reactions are presented herein), reactions were centrifuged at
10000  g for 5 min or 30 min, as indicated. Reactions
were then stopped by addition of 18 mM EDTA and 7 Al of
gel-loading buffer. After removal of supernatant fractions,
pellets were resuspended with 16 Al reaction buffer, 18 mM
EDTA, and 7 Al gel-loading buffer. As a control, some
reactions were also precipitated by incubation with 15%
TCA for 1 h on ice, centrifuged for 10 min at 10000  g,
the pellets washed with 200 Al 100% ice-cold acetone, and
centrifuged for 10 min at 10000  g. Pellets were then
resuspended as described above. The substrates and pro-
ducts were separated by denaturing PAGE then analyzed on
a phosphorimager.
SDS-PAGE of IN with L-CA
L-CA (83 AM)was incubated with recombinant full-length
IN (63 pmol) or the core region of IN (amino acids 50–212)
(61 pmol) for 30 min at 37 jC in final volume of 20 Al.
Proteins were denatured in SDS loading buffer (50 mM Tris,
pH 6.8, 20 mM DTT, 2% SDS, 0.025% bromophenol blue,
10% glycerol) heated at 95 jC for 5 min. Products were
separated by 12% SDS-PAGE; apparent molecular weights
were determined by Coomassie blue staining.
SDS-PAGE of IN with 14C-D,L-CA
Either 16000 cpm of 14C-D,L-CA or blocked 14C-D,L-CA
(200 pmol) was incubated with 4 pmol IN, or 64000 cpm of
14C-D,L-CA (800 pmol) was incubated with 20 pmol IN in
reaction buffer. After 1 h at 37 jC, the reactions were
stopped by boiling in SDS-PAGE sample buffer. Each
aliquot was separated by denaturing SDS-PAGE. The IN
band was cut out and the radioactivity present in the band
was determined by scintillation counting. Background
radioactivity from the gel was 20–50 cpm.
IN and L-CA washing experiments
The activity of each protein preparation was determined
by incubating increasing concentrations of IN with 5 nM db-
Y1 substrate for 1 h. The activity of recombinant IN
preparations were normalized to the lowest protein concen-
tration that resulted in approximately 80% conversion of db-
Y1 substrate (maximum conversion) within 1 h. For wash-
ing experiments, either IN or hen egg lysozyme (HEL) was
incubated with H2O, L-tartaric acid (L-TA), or L-CA (at both
the IC90 and the IC50) for 30 min at 37 jC. L-TA served as
the negative control (King et al., 1999) for these reactions.
Each reaction volume was 100 Al. Following the incubation,
an additional 100 Al of storage buffer was added and the
solution was centrifuged through a centrifugal concentrating
filter (Nanosep 10 kDa cutoff; Pall Corporation, East Hills,
NY) to a volume of approximately 33 Al (according to the
manufacturer’s instructions). An additional 200 Al of storage
buffer was added and the protein was again concentrated to
33 Al, constituting a single wash. This was repeated 10 times
with samples assayed after 6, 8, and 10 washes.Enzymatic activity of the washed proteins was deter-
mined as follows. For each reaction, 5 Al of the final
33 Al volume was removed and assayed in either disin-
tegration or 3V-end processing and strand transfer reac-
tions. (The 8 and 10 wash samples were concentrated an
extra 5 Al to compensate for the volume removed for the
assay.) Each integration reaction contained 5 nM substrate
(db-Y1 or V1/V2), 10 mM HEPES, pH 7.5, 10 mM
MnCl2, 10 mM DTT, 0.05% IPEGAL (Sigma), 15%
dimethyl sulfoxide (DMSO), and 1 Al of the concentrated
wash. The reaction was started with the addition of
substrate and allowed to proceed for 1 h at 37 jC.
Reactions were stopped by the addition of EDTA to a
final concentration of 18 mM and placed on ice. Next, 7
Al of loading buffer was added and the products were
resolved on a 15% denaturing PAGE. Quantification was
performed with a Storm 860 PhosphorImager (Molecular
Dynamics) using ImageQuant software.Acknowledgments
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